Sartorius Aktiengesellschaft Competitors

Sartorius Aktiengesellschaft (FRA:SRT3) and AEGON (AMS:AGN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Profitability

This table compares Sartorius Aktiengesellschaft and AEGON's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Sartorius Aktiengesellschaft and AEGON's top-line revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Sartorius Aktiengesellschaft and AEGON, as provided by MarketBeat.com.

Sartorius Aktiengesellschaft presently has a consensus target price of €321.89, indicating a potential downside of 30.40%.

Summary

Sartorius Aktiengesellschaft beats AEGON on 1 of the 1 factors compared between the two stocks.

Sartorius Aktiengesellschaft (FRA:SRT3) and American Shared Hospital Services (BME:AMS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation and risk.

Valuation & Earnings

This table compares Sartorius Aktiengesellschaft and American Shared Hospital Services' revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Sartorius Aktiengesellschaft and American Shared Hospital Services, as provided by MarketBeat.com.

Sartorius Aktiengesellschaft presently has a consensus target price of €321.89, indicating a potential downside of 30.40%.

Profitability

This table compares Sartorius Aktiengesellschaft and American Shared Hospital Services' net margins, return on equity and return on assets.

Summary

Sartorius Aktiengesellschaft beats American Shared Hospital Services on 1 of the 1 factors compared between the two stocks.

Sartorius Aktiengesellschaft (FRA:SRT3) and Bayer Aktiengesellschaft (FRA:BAYN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, analyst recommendations, profitability, institutional ownership and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Sartorius Aktiengesellschaft and Bayer Aktiengesellschaft, as reported by MarketBeat.

Sartorius Aktiengesellschaft presently has a consensus target price of €321.89, indicating a potential downside of 30.40%. Bayer Aktiengesellschaft has a consensus target price of €69.93, indicating a potential upside of 25.58%. Given Bayer Aktiengesellschaft's stronger consensus rating and higher possible upside, analysts plainly believe Bayer Aktiengesellschaft is more favorable than Sartorius Aktiengesellschaft.

Valuation & Earnings

This table compares Sartorius Aktiengesellschaft and Bayer Aktiengesellschaft's gross revenue, earnings per share and valuation.

Profitability

This table compares Sartorius Aktiengesellschaft and Bayer Aktiengesellschaft's net margins, return on equity and return on assets.

Summary

Bayer Aktiengesellschaft beats Sartorius Aktiengesellschaft on 3 of the 3 factors compared between the two stocks.

DiaSorin (BIT:DIA) and Sartorius Aktiengesellschaft (FRA:SRT3) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Earnings and Valuation

This table compares DiaSorin and Sartorius Aktiengesellschaft's top-line revenue, earnings per share and valuation.

Analyst Recommendations

This is a breakdown of recent ratings for DiaSorin and Sartorius Aktiengesellschaft, as reported by MarketBeat.

Sartorius Aktiengesellschaft has a consensus target price of €321.89, suggesting a potential downside of 30.40%.

Profitability

This table compares DiaSorin and Sartorius Aktiengesellschaft's net margins, return on equity and return on assets.

Summary

Sartorius Aktiengesellschaft beats DiaSorin on 1 of the 1 factors compared between the two stocks.

Essilor International Société Anonyme (EPA:EI) and Sartorius Aktiengesellschaft (FRA:SRT3) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations.

Valuation & Earnings

This table compares Essilor International Société Anonyme and Sartorius Aktiengesellschaft's gross revenue, earnings per share and valuation.

Profitability

This table compares Essilor International Société Anonyme and Sartorius Aktiengesellschaft's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations for Essilor International Société Anonyme and Sartorius Aktiengesellschaft, as provided by MarketBeat.

Sartorius Aktiengesellschaft has a consensus price target of €321.89, suggesting a potential downside of 30.40%. Given Sartorius Aktiengesellschaft's higher probable upside, analysts plainly believe Sartorius Aktiengesellschaft is more favorable than Essilor International Société Anonyme.

Summary

Sartorius Aktiengesellschaft beats Essilor International Société Anonyme on 2 of the 2 factors compared between the two stocks.

Fresenius SE & Co. KGaA (FRA:FRE) and Sartorius Aktiengesellschaft (FRA:SRT3) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.

Valuation and Earnings

This table compares Fresenius SE & Co. KGaA and Sartorius Aktiengesellschaft's revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Fresenius SE & Co. KGaA and Sartorius Aktiengesellschaft's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations and price targets for Fresenius SE & Co. KGaA and Sartorius Aktiengesellschaft, as provided by MarketBeat.com.

Fresenius SE & Co. KGaA presently has a consensus target price of €46.07, suggesting a potential upside of 15.69%. Sartorius Aktiengesellschaft has a consensus target price of €321.89, suggesting a potential downside of 30.40%. Given Fresenius SE & Co. KGaA's stronger consensus rating and higher possible upside, equities research analysts plainly believe Fresenius SE & Co. KGaA is more favorable than Sartorius Aktiengesellschaft.

Summary

Fresenius SE & Co. KGaA beats Sartorius Aktiengesellschaft on 3 of the 3 factors compared between the two stocks.